慢性多発性硬化症におけるリンパ球-ミクログリア-アストロ細胞軸
Martina Absinta1,2,3, Dragan Maric4, Marjan Gharagozloo5
1Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. mabsint1@jhmi.edu.
Nature
|September 9, 2021
まとめ
多発性硬化症 (MS) の病変における慢性的な脱ミエリネーションには,進行中の神経変性が含まれます. 補完成分1q (C1q) をターゲットにすることで,この白質炎症に対する潜在的な治療戦略が提供されます.
科学分野:
- 神経免疫学
- 神経変性
- 磁気共鳴画像 (MRI)
背景:
- 持続的な多発性硬化症 (MS) の病変は進行中の脱ミエリン化と軸索変性を示します.
- MRIのパラマグネティック・リム・レシオンは 進行中のMSの病変を示しています
研究 の 目的:
- MSの病変における慢性神経変性のメカニズムを解明する.
- 進行性多発性硬化症の新たな治療目標の特定
主な方法:
- 慢性性多発性硬化症のエッジのMRI誘導単核RNAシーケンシング
- グリア細胞と免疫細胞の転写プロファイリング
- マウスモデル (実験的自己免疫性脳髄炎) とヒトのMS組織でのin vivo検証
主要な成果:
- "MSで炎症した微小細胞" (MIMS) と"MSで炎症したアストロサイト"を特定する.
- MIMSは他の神経変性疾患におけるマイクログリアとトランスクリプションプロファイルを共有する.
- 補足成分1q (C1q) は,MIMSの活性化の主要な媒介物として特定されました.
結論:
- MSと他の神経変性疾患の共通のメカニズムは 共通の治療目標を示唆しています
- C1q抑制は,MSにおける慢性白質炎症に対する潜在的な治療戦略です.
- パラマグネティック・リム病変は,C1q阻害に対する治療反応のモニタリングのためのバイオマーカーとして機能する.
関連する概念動画
Glial Cells
Overview
T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Chronic Inflammation: Introduction
Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...


